Epithelioid sarcoma
Revision as of 17:21, 12 October 2020 by Warner-admin (talk | contribs) (Text replacement - "][" to "] [")
Section editor | |
---|---|
Elizabeth J. Davis, MD Vanderbilt University Nashville, TN ![]() |
Note: these are regimens tested in subtype-specific populations, please see the main soft tissue sarcoma page for other regimens.
1 regimens on this page
1 variants on this page
|
All lines of therapy
Tazemetostat monotherapy
back to top |
Regimen
FDA-recommended dose |
Study | Years of enrollment | Evidence |
---|---|---|
Gounder et al. 2017 (EZH-202) | NR in abstract | Phase II (RT) |
Note: this study has not yet been published, to our knowledge.
Targeted therapy
- Tazemetostat (Tazverik) 800 mg PO twice per day
Continued indefinitely
References
- Abstract: Mrinal M. Gounder, Silvia Stacchiotti, Patrick Schöffski, Steven Attia, Antoine Italiano, Robin Jones, George D. Demetri, Stephen Blakemore, Alicia Clawson, Scott Daigle, Scott Ribich, Maria Roche, Jill Rodstrom, Peter T.C. Ho, and Gregory Michael Cote. Phase 2 multicenter study of the EZH2 inhibitor tazemetostat in adults with INI1 negative epithelioid sarcoma (NCT02601950). Journal of Clinical Oncology 2017 35:15_suppl, 11058-11058. link to abstract CT.gov